151 related articles for article (PubMed ID: 34475049)
1. Genetic Analysis Reveals the Important Role of the
Lai YC; Wang WC
Anticancer Res; 2021 Sep; 41(9):4295-4304. PubMed ID: 34475049
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
4. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
[TBL] [Abstract][Full Text] [Related]
5. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
Banks RE; Tirukonda P; Taylor C; Hornigold N; Astuti D; Cohen D; Maher ER; Stanley AJ; Harnden P; Joyce A; Knowles M; Selby PJ
Cancer Res; 2006 Feb; 66(4):2000-11. PubMed ID: 16488999
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
Kondo K; Yao M; Yoshida M; Kishida T; Shuin T; Miura T; Moriyama M; Kobayashi K; Sakai N; Kaneko S; Kawakami S; Baba M; Nakaigawa N; Nagashima Y; Nakatani Y; Hosaka M
Genes Chromosomes Cancer; 2002 May; 34(1):58-68. PubMed ID: 11921283
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
[TBL] [Abstract][Full Text] [Related]
9. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
[TBL] [Abstract][Full Text] [Related]
10. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
[TBL] [Abstract][Full Text] [Related]
11. The Clinicopathological Significance of Epigenetic Silencing of VHL Promoter and Renal Cell Carcinoma: A Meta-Analysis.
Yang L; Zhao Z; Zhao S; Chen C; Cong X; Li Z; Ren M
Cell Physiol Biochem; 2016; 40(6):1465-1472. PubMed ID: 27997886
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau exonic methylation analysis using MALDI-TOF mass spectrometry.
Lian F; Sreedharan S; Arnold RS; Master VA; Ogan K; Pattaras JG; Roberts DL; Petros JA
J Urol; 2014 Nov; 192(5):1528-33. PubMed ID: 24704013
[TBL] [Abstract][Full Text] [Related]
13. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
[TBL] [Abstract][Full Text] [Related]
14. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
15. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
16. Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma.
Schouten LJ; van Dijk BA; Oosterwijk E; van Engeland M; Hulsbergen-van de Kaa CA; Kiemeney LA; Goldbohm RA; Kester A; de Vogel S; Schalken JA; van den Brandt PA
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3543-50. PubMed ID: 19064569
[TBL] [Abstract][Full Text] [Related]
17. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
18. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.
Inoue H; Nonomura N; Kojima Y; Shiba M; Oka D; Arai Y; Nakayama M; Takayama H; Nishimura K; Mori H; Okuyama A
Nephrol Dial Transplant; 2007 Jul; 22(7):2052-5. PubMed ID: 17438007
[TBL] [Abstract][Full Text] [Related]
20. [Inactivation of the VHL gene in sporadic clear cell renal cancer].
Mikhaĭlenko DS; Kurynin RB; Popov AM; Kariakin OB; Enikeev ME; Aliaev IuG; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2008; 42(1):71-7. PubMed ID: 18389622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
